Latest & greatest articles for verapamil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on verapamil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on verapamil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for verapamil

1. Verapamil

Verapamil Top results for verapamil - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for verapamil The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations.

Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Intravenous verapamil for termina... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1980 ) Volume: 93 , Issue: 5 , Pages: 682-689 PubMed: Available from or Find this paper at: Abstract We evaluated efficacy and mechanisms (...) of the antiarrhythmic action of verapamil in 20 patients with sustained supraventricular tachycardia. Two patients had sinus nodal re-entrant tachycardia, nine atrioventricular (AV) nodal re-entrant tachycardia, and nine AV reciprocating tachycardia associated with the Wolff-Parkinson-White syndrome. The study design comprised a double-blind, randomized, cross-over phase using a 0.075 mg/kg dose of verapamil versus placebo and an open-label phase using a 0.15 mg/kg dose of verapamil. The overall results of both

Annals of Internal Medicine2013

3. Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials

Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials Zou Z, Xu FY, Wang L, An MM, Zhang H, Shi XY CRD summary This review of trandolapril/verapamil combination (...) therapy found that it provided better blood pressure control and renoprotective effects compared to verapamil alone without increasing adverse effects and reduced diastolic blood pressure and albuminuria compared to trandolapril alone. Aside from a lack of information about study quality, this was a good review and its conclusions seem reliable. Authors' objectives To evaluate the efficacy and tolerability of the trandolapril/verapamil combination for blood pressure control and renoprotection

DARE.2011

4. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis

The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis Delaney B, Loy J, Kelly AM CRD summary This review (...) concluded that adenosine and verapamil had similar efficacy in treating paroxysmal supraventricular tachycardia. Adenosine had a higher rate of overall adverse events than verapamil but verapamil had a higher rate of hypertension. Conclusions on efficacy are likely to be reliable although generalisability is unclear; there is more uncertainty surrounding the adverse events, particularly for hypotension. Authors' objectives To assess the relative effectiveness of adenosine compared to verapamil

DARE.2011

6. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.

Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. 12709465 2003 04 23 2003 05 06 2016 10 17 0098-7484 289 16 2003 Apr 23-30 JAMA JAMA Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. 2073-82 Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial. To determine (...) whether initial therapy with controlled-onset extended-release (COER) verapamil is equivalent to a physician's choice of atenolol or hydrochlorothiazide in preventing cardiovascular disease. Double-blind, randomized clinical trial conducted at 661 centers in 15 countries. A total of 16 602 participants diagnosed as having hypertension and who had 1 or more additional risk factors for cardiovascular disease were enrolled between September 1996 and December 1998 and followed up until December 31, 2000

JAMA2003

7. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. 14657064 2003 12 05 2003 12 11 2016 10 17 1538-3598 290 21 2003 Dec 03 JAMA JAMA A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled (...) patients aged 50 years or older, which was conducted September 1997 to February 2003 at 862 sites in 14 countries. Patients were randomly assigned to either CAS (verapamil sustained release) or NCAS (atenolol). Strategies specified dose and additional drug regimens. Trandolapril and/or hydrochlorothiazide was administered to achieve blood pressure goals according to guidelines from the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment

JAMA2003

8. Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia.

Diltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia. BACKGROUND: Tardive dyskinesia (TD) is a potentially disfiguring movement disorder of the orofacial region often caused by use of neuroleptic drugs. A wide range of strategies have been used to help manage TD and, for those who are unable to have their antipsychotic medication stopped or substantially changed, the calcium-channel blocking group of drugs (diltiazem, nifedipine, nimodipine, verapamil) has

Cochrane2000

9. Verapamil use in patients with cardiovascular disease: an overview of randomized trials

Verapamil use in patients with cardiovascular disease: an overview of randomized trials Verapamil use in patients with cardiovascular disease: an overview of randomized trials Verapamil use in patients with cardiovascular disease: an overview of randomized trials Pepine C J, Faich G, Makuch R Authors' objectives To present an overview of randomised trials investigating the use of verapamil in patients with cardiovascular disease. Searching MEDLINE was searched from January 1966 to April 1997 (...) ) using the keyword 'verapamil' alone and in combination with the following terms: 'clinical trial', 'MI', 'angina', and 'hypertension'. Further searches of the Science Citation Index and Current Contents were carried out (search dates unclear). All of the searches were limited to publications in the English language. The bibliographies of retrieved articles and other reviews were also examined for additional studies. Three investigators knowledgeable with the verapamil literature reviewed the final

DARE.1998

10. A systematic review and meta-analysis of the incidence of cancer in randomized, controlled trials of verapamil

A systematic review and meta-analysis of the incidence of cancer in randomized, controlled trials of verapamil A systematic review and meta-analysis of the incidence of cancer in randomized, controlled trials of verapamil A systematic review and meta-analysis of the incidence of cancer in randomized, controlled trials of verapamil Dong E W, Connelly J E, Borden S P, Yorzyk W, Passov D G, Kupelnick B, Luo D H, Ross S D Authors' objectives To assess the incidence of cancer in patients receiving (...) verapamil for the treatment of hypertension, angina pectoris or cardiac arrhythmias. Searching Medlars was searched from 1966 to October 20, 1996 for trials conducted in humans, using the MeSH term 'verapamil'. During the course of the project, Current Contents was also searched on a weekly basis. The searches were limited to papers published in the English language. The reference lists of all the retrieved clinical trials and review articles were also examined, and an attempt was made to obtain

DARE.1997

11. Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group.

Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group. 2510877 1990 01 02 1990 01 02 2013 11 21 0959-8138 299 6704 1989 Oct 07 BMJ (Clinical research ed.) BMJ Verapamil versus hydrochlorothiazide in the treatment of hypertension: results of long term double blind comparative trial. Verapamil versus Diuretic (VERDI) Trial Research Group. 881-6 To compare the efficacy (...) and tolerability of hydrochlorothiazide, sustained release verapamil, and their combination in patients with mild to moderate hypertension. Randomised multicentre trial of 48 weeks' duration with a double blind comparison of hydrochlorothiazide and verapamil followed by an open trial of combined treatment for patients not achieving the target diastolic blood pressure (less than 90 mm Hg) during treatment with a single drug. Outpatient departments in 10 clinics and 10 private practices of general practitioners

BMJ1989 Full Text: Link to full Text with Trip Pro

12. Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol.

Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. 3144329 1989 02 07 1989 02 07 2013 11 21 0959-8138 297 6657 1988 Nov 05 BMJ (Clinical research ed.) BMJ Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. 1155-9 To compare responses of blood pressure to the calcium antagonist verapamil and the beta blocker metoprolol in black (...) completed the trial. Patients given slow release verapamil 120 mg or 240 mg twice daily with placebo or metoprolol 50 mg or 100 mg twice daily with placebo. Treatment for diabetes (diet alone or with oral hypoglycaemic drugs) remained unchanged. Comparison of changes in blood pressure in the two groups taking both drugs. Metoprolol had little effect on blood pressure in black patients (mean fall 4.0 mm Hg systolic (95% confidence interval -2.5 to 10.4 mm Hg), 4.3 mm Hg diastolic (-0.8 to 9.5)) but more

BMJ1988 Full Text: Link to full Text with Trip Pro

13. A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response.

A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. 3531560 1986 11 07 1986 11 07 2016 10 17 0098-7484 256 16 1986 Oct 24-31 JAMA JAMA A comparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. 2214-21 We compared verapamil and propranolol hydrochloride for monotherapy of hypertension. Verapamil lowered blood pressure (BP) more effectively than propranolol in black (...) and white patients. Verapamil was equally effective in blacks and whites, whereas propranolol was more effective in whites. Heart rate was reduced by 6.0 beats per minute by verapamil, and by 13.6 beats per minute by propranolol. In blacks, verapamil lowered systolic BP 16.9 vs 8.1 mm Hg for propranolol; verapamil reduced diastolic BP 12.8 vs 8.6 mm Hg for propranolol. In whites, verapamil lowered systolic BP 19.0 vs 12.7 mm Hg for propranolol; verapamil reduced diastolic BP 16.7 vs 12.3 mm Hg

JAMA1986

14. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study.

Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. 6355533 1983 12 17 1983 12 17 2016 10 17 0098-7484 250 18 1983 Nov 11 JAMA JAMA Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. 2500-2 We undertook a double-blind, placebo-controlled study to determine the effectiveness of verapamil hydrochloride for the prophylaxis of migraine. Twelve patients were given either verapamil hydrochloride, 80 mg four times daily, or placebo in random order (...) during two consecutive three-month periods. Migraine frequency, severity, and duration were quantified by daily logs and monthly questionnaires. Ten of the 12 patients had fewer migraines during verapamil therapy. Migraine frequency decreased from 6.7 to 3.8 migraines per patient per month, for a mean decrease of 49%. Headache unit index fell from an average of 0.61 to 0.44. We conclude that verapamil is effective in the prophylaxis of migraine and that verapamil might be considered one alternative

JAMA1983

15. A controlled trial of verapamil for Prinzmetal's variant angina.

A controlled trial of verapamil for Prinzmetal's variant angina. 6782480 1981 05 13 1981 05 13 2013 11 21 0028-4793 304 15 1981 Apr 09 The New England journal of medicine N. Engl. J. Med. A controlled trial of verapamil for Prinzmetal's variant angina. 862-6 To assess the efficacy and safety of verapamil in variant angina pectoris, we entered 16 patients in a double-blind, randomized trial of nine months, duration. During treatment with verapamil, the frequency of angina fell substantially (...) (12.6 +/- 25.9 chest pains per week with placebo, 1.7 +/- 2.8 pains per week with verapamil, mean +/- S.D.; P less than 0.01), as did the use of nitroglycerin tablets (14.4 +/- 34.4 tablets per week with placebo, 2.1 +/- 3.3 tablets per week with verapamil; P less than 0.05). The number of hospitalizations for clinical instability was significantly lower with verapamil (P less than 0.01). The number of episodes of transient ST-segment deviation during treatment with verapamil was reduced (33.1

NEJM1981

16. Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise.

Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise. 6103208 1980 07 12 1980 07 12 2015 06 16 0140-6736 1 8173 1980 Apr 19 Lancet (London, England) Lancet Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise. 841-4 The efficacy of verapamil (360 mg daily) in the treatment of patients with chronic stable angina pectoris was compared with placebo. 28 patients were studied in a placebo-controlled (...) double-blind crossover trial of 2 weeks each and afterwards on long-term verapamil. Exercise tests were performed at the end f the placebo period, and after 2 weeks and 4 weeks on verapamil. On placebo, angina developed in all 28 patients during treadmill tests; the mean exercise time was 6.6 min (SEM +/- 0.5 min). The mean exercise time increased to 9.2 (+/- 0.8) min at 2 weeks, and 11.2 (+/- 0.8) min at 4 weeks on verapamil. In 15 and 20 patients out of the 28 angina did not develop during

Lancet1980